Total for the last 12 months
number of access : ?
number of downloads : ?
ID 119036
Author
Bando, Hiroshi Tokushima University|Medical Research|Integrative Medicine Japan|Japan Low Carbohydrate Diet Promotion Association KAKEN Search Researchers
Keywords
sodium-glucose co-transporter-2 inhibitor (SGLT2i)
sarcopenia
visceral fat area (VFA)
skeletal muscle index (SMI)
bone mineral content (BMC)
Content Type
Journal Article
Description
Regarding pharmacological therapy for diabetes, sodium-glucose co-transporter-2 inhibitor (SGLT2i) has been in focus for various clinical efficacy. They include cardiovascular disease, chronic heart failure (CHF) and chronic kidney disease (CKD). Various discussion has been observed concerning the relationship among diabetes, frailty, sarcopenia, SGLT2i, aging and senile syndrome. By SGLT2i, weight and visceral fat area (VFA) are decreased, and the results of skeletal muscle index (SMI) and bone mineral content (BMC) vary in some reports. Using abdominal CT, bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), muscle mass and BMC have been lately studied. SGLT2i may maintain muscle mass and function.
Journal Title
International Journal of Complementary & Alternative Medicine
ISSN
23811803
Publisher
MedCrave Publishing
Volume
15
Issue
4
Start Page
220
End Page
222
Published Date
2022-07-29
Rights
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and build upon your work non-commercially.
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences